| Company Name: |
ShangHai Biochempartner Co.,Ltd
|
| Tel: |
177-54423994 17754423994 |
| Email: |
2853530910@QQ.com |
| Products Intro: |
Product Name:Clervonafusp Alfa
CAS:2145123-44-8
Purity:95% Package:100ug;500ug;1mg
|
| Company Name: |
Wuhan Chemstan Biotechnology Co., Ltd.
|
| Tel: |
027-65317797 15926423062 |
| Email: |
422450190@qq.com |
| Products Intro: |
Product Name:Clervonafusp Alfa
CAS:2145123-44-8
Purity:>95% Package:100ug;200ug;1mg
|
| Company Name: |
Biolab Reagents
|
| Tel: |
027-65279366 18108604356 |
| Email: |
products@biolabreagent.com |
| Products Intro: |
Product Name:Research Grade Clervonafusp Alfa (DHC80002)
CAS:2145123-44-8
Purity:PAGE:>95% Package:100ug;1mg
|
| Company Name: |
Wuhan Acumen Bio-Technology Co.,ltd
|
| Tel: |
027-027-16602739303 16602739303 |
| Email: |
673003916@qq.com |
| Products Intro: |
CAS:2145123-44-8
Purity:95%,98% HPLC Package:5G;1G
|
| Company Name: |
Atagenix Laboratories
|
| Tel: |
027-87008169 17762441161 |
| Email: |
info@atagenix.com |
| Products Intro: |
Product Name:Research Grade Clervonafusp Alfa
CAS:2145123-44-8
Purity:>95% Package:100ug
|
|
| | Clervonafusp Alfa Basic information |
| Product Name: | Clervonafusp Alfa | | Synonyms: | Clervonafusp Alfa;Research Grade Clervonafusp Alfa (DHC80002);Research Grade Clervonafusp Alfa;Clervonafusp | | CAS: | 2145123-44-8 | | MF: | | | MW: | 0 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File | ![Clervonafusp Alfa Structure]() |
| | Clervonafusp Alfa Chemical Properties |
| | Clervonafusp Alfa Usage And Synthesis |
| Uses | Clervonafusp alfa (VAL-1221) is a fusion protein targeting both cytosolic and lysosomal glycogen. Clervonafusp alfa is comprised of the Fab portion of a cell-penetrating antibody and recombinant human acid alpha glucosidase (rhGAA), the former utilizing the nucleoside transporter ENT-2 to gain access to the cytosol, and the latter enters lysosomes via mannose-6-phosphate receptors (M6PRs). Clervonafusp alfa can be used for late-onset Pompe disease research[1]. | | References | [1] Kishnani P, et al. Safety and efficacy of VAL-1221, a novel fusion protein targeting cytoplasmic glycogen, in patients with late-onset Pompe disease. Molecular Genetics & Metabolism, 2019, 126(2):S85-S86. |
| | Clervonafusp Alfa Preparation Products And Raw materials |
|